FDA approves marketing of octreotide.
D002276:Carcinoid Tumor / Q000150:complications / Q000188:drug therapy*; D003132:Commerce; D003967:Diarrhea / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007414:Intestinal Neoplasms / Q000150:complications / Q000188:drug therapy*; D015282:Octreotide / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D015282:Octreotide